Endpoint modified ex-post, which means it was a failure. And the 17 other secondary endpoints were failures. As well as the primary endpoint. Then, zero regulators, across all countries in the world, were interested in approving Leronlimab for mild/moderate patients based on that study. It's pretty obvious: CD10 was a huge failure
Misiu143- the more I look over our CD10 results the more I wonder why we didn’t get approval other than we didn’t ask because I can’t think of a drug that has shown to be more effective in MM am I missing something ?
Market Data 
Markets 
AI
